Welcome to Dispensed Daily, your daily dose of healthcare news from Business Insider.
New to the newsletter? You can sign up here to get this email in your inbox every day.
Let’s dive into today’s top stories from the healthcare team.
The presentation digital health startup Cedar used in convincing Andreessen Horowitz to lead its $102 million round
In healthcare startup-land, the week got off to a start with a fresh $102 million round for Cedar, a four-year-old New York startup that’s trying to make medical billing less of a pain for patients.
Zach Tracer and I got an exclusive look at the pitch deck Cedar used in the round, which was led by Andreessen Horowitz and included venture debt from JPMorgan.
The presentation shows how Cedar plans to expand beyond its initial offering, which helped make it easier to pay for a doctor visit.
You can see the full presentation here>>
We got an exclusive look at the presentation that Cedar used to convince investors like Andreessen Horowitz and JPMorgan to bet $102 million on the digital health startup’s vision of a better way of paying for healthcare
The $96 billion biotech Gilead will start testing a new version of the first effective coronavirus treatment, and it could make remdesivir available to vastly more patients
The biotech giant that developed the first effective coronavirus treatment is now looking to expand its impact.
Gilead Sciences CEO Daniel O’Day said Monday that the company would start testing an inhaled version of the antiviral drug remdesivir in August.
Currently, the drug is given as an intravenous infusion.
If remdesivir is effective when given through a nebulizer, that “could have significant implications in helping to stem the tide of the pandemic,” O’Day wrote in an open letter.
Read the full story from Andrew Dunn here>>
Your blood type may impact how hard you get hit by the coronavirus, new research shows
New research suggests there could be a link between a patient’s blood type and their risk of a severe coronavirus infection.
An analysis of thousands of coronavirus patients in Spain and Italy showed that people with blood type A are 50% more likely to develop severe symptoms and require ventilation.
The researchers also noted that people with blood type O are less likely to contract severe infections.
Read the full story from Insider’s Aylin Woodward here>>
More stories we’re reading:
As Texas reports 10th straight day of record-high coronavirus hospitalizations, ex-FDA chief warns outbreaks could be ‘tipping over into exponential growth’ (Business Insider)
Here’s what it’s like to donate convalescent plasma (Fierce Healthcare)
Dozens of drugmakers are racing to develop coronavirus vaccines. Here’s exactly how they see 2020 playing out in the sprint for a cure. (Business Insider)
How Hawaii became a coronavirus success story (Politico)
Thanks for reading Dispensed Daily, a daily version of my weekly Dispensed email. What do you think? What would you like to see every …read more
Source:: Business Insider